We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Netscientific Plc | LSE:NSCI | London | Ordinary Share | GB00BN4R5Q82 | ORD 5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.50 | -0.79% | 62.50 | 60.00 | 65.00 | 63.00 | 62.50 | 63.00 | 29,011 | 15:03:36 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 1M | -3.09M | -0.1312 | -4.76 | 14.73M |
From May 2019 to May 2024
TIDMNSCI
RNS Number : 0174X
NetScientific PLC
25 April 2019
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014
NetScientific plc
("NetScientific" or the "Company")
Resignation of CEO
NetScientific announces that it has accepted today the resignation of François Martelet as its CEO. François has resigned to assist the Company in reducing its central costs and to pursue other career opportunities. He will depart on 30 April 2019 in accordance with the terms of his service agreement.
Ian Postlethwaite, currently CFO and Company Secretary of NetScientific, will henceforth combine these roles with that of CEO.
The Company also announces that the lease of the Company's headquarters at 6 Bevis Marks London EC3A 7BA was terminated on 29 March 2019 and it continues to review all other activities to manage its cash resources effectively.
Commenting on his resignation, François Martelet stated: "Out of the five assets we selected in 2015 I am pleased to report that three have made it to the commercial stage (Vortex Biosciences, ProAxsis Limited and Wanda, Inc.). Glycotest Inc. concluded its Series A financing round with Shanghai Fosun Pharmaceutical Co., Ltd. and PDS Biotechnology Corporation completed its all share merger with Edge Therapeutics.
I would like to thank the NetScientific Board, in particular Sir Richard Sykes, for the great support provided over the last four years."
Sir Richard Sykes, Chairman of the Company stated: "The Board would like to put on record its gratitude to François for his leadership of NetScientific since 2015 in a challenging IP commercialisation environment and wishes him every success in his future interests. We will seek to make the most of our reduced central costs with the aim of maximising the potential in our remaining portfolio companies."
For more information, please contact:
NetScientific Tel: +44 (0)20 3514 Ian Postlethwaite, CFO 1800 WH Ireland Limited (NOMAD, Financial Adviser Tel: +44 (0)20 7220 and Broker) 1666 Chris Fielding / Jessica Cave
About NetScientific
NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases.
For more information, please visit the website at http://www.NetScientific.net
END
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
BOABZLLLKZFBBBE
(END) Dow Jones Newswires
April 25, 2019 02:01 ET (06:01 GMT)
1 Year Netscientific Chart |
1 Month Netscientific Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
